259 related articles for article (PubMed ID: 23322515)
1. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
Matro J; Giubellino A; Pacak K
Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
[TBL] [Abstract][Full Text] [Related]
2. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
[TBL] [Abstract][Full Text] [Related]
3. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
4. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
Vicha A; Musil Z; Pacak K
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models.
Bullova P; Cougnoux A; Abunimer L; Kopacek J; Pastorekova S; Pacak K
Oncotarget; 2016 Jun; 7(26):40531-40545. PubMed ID: 27244895
[TBL] [Abstract][Full Text] [Related]
6. Targeting NAD
Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
[No Abstract] [Full Text] [Related]
7. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
8. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
10. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.
Lendvai N; Pawlosky R; Bullova P; Eisenhofer G; Patocs A; Veech RL; Pacak K
Endocrinology; 2014 Jan; 155(1):27-32. PubMed ID: 24189137
[TBL] [Abstract][Full Text] [Related]
11. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
[No Abstract] [Full Text] [Related]
13. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
Vicha A; Taieb D; Pacak K
Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
[TBL] [Abstract][Full Text] [Related]
14. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
16. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
[TBL] [Abstract][Full Text] [Related]
17. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
Elston MS; Meyer-Rochow GY; Conaglen HM; Clarkson A; Clifton-Bligh RJ; Conaglen JV; Gill AJ
Hum Pathol; 2015 Mar; 46(3):390-6. PubMed ID: 25554089
[TBL] [Abstract][Full Text] [Related]
18. Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function.
Rapizzi E; Fucci R; Giannoni E; Canu L; Richter S; Cirri P; Mannelli M
Endocr Relat Cancer; 2015 Jun; 22(3):409-17. PubMed ID: 25808177
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
[TBL] [Abstract][Full Text] [Related]
20. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
